Home›Clinical trials›Washington

GLP-1 clinical trials in Washington: 24 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

24 GLP-1 clinical trials are recruiting at 35 sites in 11 cities across Washington. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Washington

  1. A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people calm psoriasis.

    A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    The registry lists a near-identical study as NCT06864026.

    Phase 4. Eli Lilly and Company plans to enroll 200 participants.

    Who can join. Adults 18+, have psoriasis, BMI 27+.

    2 sites in Washington

    NCT06857942 on ClinicalTrials.gov. See whether you qualify.

  2. A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people ease psoriatic arthritis.

    A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    The registry lists a near-identical study as NCT06857942.

    Phase 4. Eli Lilly and Company plans to enroll 200 participants.

    Who can join. Adults 18+, have psoriatic arthritis, BMI 27+.

    2 sites in Washington

    • Seattle Rheumatology Associates PLLC, Seattle
    • Arthritis Northwest, PLLC, Spokane Valley

    NCT06864026 on ClinicalTrials.gov. See whether you qualify.

  3. A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes

    Phase 4. University of Washington plans to enroll 50 participants.

    Who can join. Adults 40 to 65, have type 2 diabetes.

    1 site in Washington

    • University of Washington - Harborview Medical Center, Seattle. 206-744-8305

    NCT05780905 on ClinicalTrials.gov. See whether you qualify.

  1. A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with Prader-Willi syndrome lose weight.

    Tirzepatide in PWS, HO and GNSO

    Phase 4. Grace Kim plans to enroll 36 participants.

    Who can join. Adults 18 to 26, have Prader-Willi syndrome, BMI 30+.

    1 site in Washington

    NCT06901245 on ClinicalTrials.gov. See whether you qualify.

  2. A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Eli Lilly and Company plans to enroll 4,500 participants.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    3 sites in Washington

    • Washington Gastroenterology - Bellevue, Bellevue. 425-454-4768
    • UW Medicine Diabetes Institute, Seattle
    • Washington Gastroenterology - Tacoma, Tacoma. 253-272-5127

    NCT07165028 on ClinicalTrials.gov. See whether you qualify.

  3. A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Boehringer Ingelheim plans to enroll 1,800 participants.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    2 sites in Washington

    • Velocity Clinical Research, Seattle, Seattle. 833-602-2368
    • Velocity Clinical Research-Spokane-69716, Spokane. 833-602-2368

    NCT06632444 on ClinicalTrials.gov. See whether you qualify.

  4. A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Phase 3. Boehringer Ingelheim plans to enroll 1,590 participants.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

    2 sites in Washington

    • Velocity Clinical Research, Seattle, Seattle. 833-602-2368
    • Velocity Clinical Research-Spokane-69716, Spokane. 833-602-2368

    NCT06632457 on ClinicalTrials.gov. See whether you qualify.

  5. A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Eli Lilly and Company plans to enroll 125 participants.

    Who can join. Children and teens 6 to 17, have obesity.

    2 sites in Washington

    • Seattle Children's Research Institute - Hughes Building - PIN, Seattle
    • MultiCare Health System - Mary Bridge Children's Health Center, Tacoma

    NCT06672549 on ClinicalTrials.gov. See whether you qualify.

  6. A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people reduce bladder leaks.

    A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

    Phase 3. Eli Lilly and Company plans to enroll 1,000 participants.

    Who can join. Adults 18+, women only, have stress urinary incontinence (bladder leaks), BMI 27+.

    2 sites in Washington

    NCT07202884 on ClinicalTrials.gov. See whether you qualify.

  7. A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people improve blood flow in the legs.

    Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

    Phase 3. Eli Lilly and Company plans to enroll 1,205 participants.

    Who can join. Adults 18+, have peripheral artery disease (poor blood flow in the legs), BMI 23+.

    2 sites in Washington

    NCT07223593 on ClinicalTrials.gov. See whether you qualify.

The other 14 studies recruiting in Washington

  1. A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. AstraZeneca plans to enroll 1,200 participants.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    2 sites in Washington

    • Research Site, Renton
    • Research Site, Seattle

    NCT07662213 on ClinicalTrials.gov. See whether you qualify.

  2. A study testing whether a GLP-1 medicine, semaglutide, can help people with type 1 diabetes lower blood sugar.

    Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes

    Phase 3. University of Colorado, Denver plans to enroll 60 participants.

    Who can join. Adults 18 to 49, have type 1 diabetes, BMI 20+.

    1 site in Washington

    • University of Washington Medicine Diabetes Institute (UWMDI), Seattle. 504-521-7822

    NCT05819138 on ClinicalTrials.gov. See whether you qualify.

  3. A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with ulcerative colitis calm gut inflammation.

    Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative

    Phase 3. Eli Lilly and Company plans to enroll 350 participants.

    Who can join. Adults 18 to 70, have ulcerative colitis, BMI 27+.

    1 site in Washington

    NCT06937086 on ClinicalTrials.gov. See whether you qualify.

  4. A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with Crohn's disease calm gut inflammation.

    Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity

    Phase 3. Eli Lilly and Company plans to enroll 290 participants.

    Who can join. Adults 18 to 70, have Crohn's disease, BMI 27+.

    1 site in Washington

    NCT06937099 on ClinicalTrials.gov. See whether you qualify.

  5. A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people ease joint pain.

    A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

    Phase 3. Eli Lilly and Company plans to enroll 800 participants.

    Who can join. Adults 18+, have osteoarthritis (joint pain), BMI 27+.

    1 site in Washington

    • Northwest Clinical Research Center, Bellevue

    NCT07153471 on ClinicalTrials.gov. See whether you qualify.

  6. A study testing whether a GLP-1 medicine, semaglutide, can help people with alcohol use disorder drink less.

    Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

    Phase 3. VA Office of Research and Development plans to enroll 622 participants.

    Who can join. Adults 18 to 80, have alcohol use disorder, BMI 21+.

    1 site in Washington

    • VA Puget Sound HCS - Seattle and Tacoma, Tacoma. 253-583-2026

    NCT07218354 on ClinicalTrials.gov. See whether you qualify.

  7. A study testing whether a study medicine from Amgen, Maridebart Cafraglutide, can help people lose weight.

    A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1

    Phase 3. Amgen plans to enroll 300 participants.

    Who can join. Adults 18+, have obesity or are overweight, BMI 25+.

    1 site in Washington

    • Eastside Research Associates Health Research, Redmond

    NCT07575399 on ClinicalTrials.gov. See whether you qualify.

  8. A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

    A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Phase 3. Boehringer Ingelheim plans to enroll 600 participants.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    1 site in Washington

    NCT07754461 on ClinicalTrials.gov. See whether you qualify.

  9. A study testing whether a GLP-1 medicine, semaglutide, can help people with diabetic kidney disease protect their kidneys.

    Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

    Phase 2. University of Washington plans to enroll 60 participants.

    Who can join. Adults 18+, have diabetic kidney disease, BMI 20+.

    2 sites in Washington

    NCT05822609 on ClinicalTrials.gov. See whether you qualify.

  10. A study testing whether an investigational medicine from Lilly, LY3305677, can help people lose weight.

    A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity

    Phase 2. Eli Lilly and Company plans to enroll 1,481 participants.

    Who can join. Adults 18 to 75, have obesity, BMI 27+.

    1 site in Washington

    • Central Washington Health Services Association d/b/a Confluence Health, Wenatchee. 509-436-4050

    NCT06143956 on ClinicalTrials.gov. See whether you qualify.

  11. A study testing whether an investigational medicine from Novo Nordisk, NNC0519-0130, can help people with chronic kidney disease protect their kidneys.

    A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living

    Phase 2. Novo Nordisk A/S plans to enroll 465 participants.

    Who can join. Adults 18+, have chronic kidney disease, BMI 27+.

    1 site in Washington

    • Providence Medical Research Center, Spokane

    NCT06717698 on ClinicalTrials.gov. See whether you qualify.

  12. A study testing whether an investigational medicine from Lilly, LY3457263, can help people with type 2 diabetes lower blood sugar.

    A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

    Phase 2. Eli Lilly and Company plans to enroll 240 participants.

    Who can join. Adults 18 to 75, have type 2 diabetes, BMI 27+.

    1 site in Washington

    NCT06897475 on ClinicalTrials.gov. See whether you qualify.

  13. A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people lose weight.

    A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

    Phase 2. Novo Nordisk A/S plans to enroll 230 participants.

    Who can join. Adults 18+, have obesity, BMI 30+.

    1 site in Washington

    • Rainier Clin Res Ctr Inc, Renton

    NCT07639021 on ClinicalTrials.gov. See whether you qualify.

  14. A study testing whether an investigational medicine from Novo Nordisk, UBT251, can help people with type 2 diabetes lower blood sugar.

    A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Novo Nordisk A/S plans to enroll 300 participants.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    1 site in Washington

    • The Vancouver Clinic, Vancouver

    NCT07668388 on ClinicalTrials.gov. See whether you qualify.

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Check price →

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
Written and edited by John SamarasAbout this siteContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.